This information is intended for use by US healthcare providers only. Visit the RELIEF Clinical Trial >>

Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment

Learn More About a Phase III Study for Patients with Polycythemia Vera

A phase III study investigating ruxolitinib—an oral JAK1 and JAK2 inhibitor

On this Web site, you will find information on the RESPONSE clinical trial evaluating the investigational agent ruxolitinib for the treatment of polycythemia vera. Additional useful resources include trial recruitment information and brief overviews of selected topics such as polycythemia vera, the Janus kinase (JAK) pathway, and preliminary clinical results.

This Web site is for US healthcare professionals only for the RESPONSE trial. Ruxolitinib is an investigational compound for the treatment of patients with polycythemia vera (PV). Its efficacy and safety have not been established in this patient population. There is no guarantee that this compound will become commercially available for use in PV patients.

Last updated May 2012.